Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Identify the Optimal Weekly Oral Dose of Ecnoglutide (VRB-101) for Maintaining Body Weight in Participants With Obesity or Overweight Who Have Weight-Related Comorbidities

NCT07553299 is registered in ClinicalTrials.gov with Verdiva Bio Dev Limited as lead sponsor.

NCT NCT07553299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07553299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Identify the Optimal Weekly Oral Dose of Ecnoglutide (VRB-101) for Maintaining Body Weight in Participants With Obesity or Overweight Who Have Weight-Related Comorbidities
Lead sponsor
Verdiva Bio Dev Limited
Phase
Phase 2
Overall status
Terminated
Start date
June 12, 2026
Completion date
September 11, 2026
Enrollment
8 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, overweight, weight maintenance